MAP2K7 and central nervous system cancer: Recently, Jain et al. [102] reported that a combination of BRAF-inhibitor dabrafenib and MEK-inhibitor trametinib enhanced treatment efficacies in pediatric low-grade-glioma carrying KIAA1549-BRAF fusion.